Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 4:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 11,050 matching trials from the live ClinicalTrials.gov search.
Conditions
Ewing's Sarcoma, Leukemia, Lymphoma, Brain Tumors, Rhabdomyosarcoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 40 Years
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
CP, Gait Disorders, Neurologic, Locomotion Disorder, Neurologic
Interventions
Whole body vibration training
Other
Lead sponsor
University of Texas, El Paso
Other
Eligibility
8 Years to 12 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Completed Phase 4 Interventional Results available

Tocilizumab Plus a Short Prednisone Taper for GCA

NCT03726749
Conditions
Giant Cell Arteritis
Interventions
Tocilizumab, Prednisone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional Results available

Improving Coordination and Transitions of Care in Stroke Patients

NCT02642744
Conditions
Stroke, Transient Ischemic Attack
Interventions
Nursing care model
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated No phase listed Observational Accepts healthy volunteers

CCM Blood Biomarker Validation Study

NCT05148663
Conditions
Hemorrhagic Stroke, Intracerebral, Cerebral Cavernous Malformation
Interventions
CCM Hemorrhagic Panel
Diagnostic Test
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
10 Years to 78 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Conditions
Traumatic Brain Injury, Blast Injuries
Interventions
3T Connectome MRI, 7 Tesla MRI, TSPO PET, Tau PET, Cognitive and Behavioral Assessments, Blood Biomarkers
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 45 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Orthostatic Hypotension
Interventions
Droxidopa, Midodrine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Juvenile Myoclonic Epilepsy
Interventions
JZP926 capsule, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more
Completed Not applicable Interventional Accepts healthy volunteers

Brain Mechanisms Supporting Meditation-based Analgesia

NCT03414138
Conditions
Pain
Interventions
Mindfulness Training, Book Listening Control
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Not applicable Interventional Accepts healthy volunteers

Brain-computer Interface Commercial Readiness

NCT06521736
Conditions
Non-Verbal Communication, Degenerative Neurologic Disease
Interventions
AAC-BCI device
Device
Lead sponsor
Kendrea Garand
Other
Eligibility
14 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Completed Phase 2Phase 3 Interventional Results available

VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease

NCT02534844
Conditions
Niemann-Pick Disease, Type C
Interventions
Parts A/B: Adrabetadex, Parts A/B: Sham Control
Drug · Other
Lead sponsor
Mandos LLC
Industry
Eligibility
4 Years to 21 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 11 more
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, paclitaxel, topotecan hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Neurologic Manifestations, Premature Birth, Hypoxia-Ischemia, Brain
Interventions
EEG, NIRS
Device
Lead sponsor
Sharp HealthCare
Other
Eligibility
Up to 72 Hours
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
San Diego, California
Conditions
Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma
Interventions
OKN-007
Drug
Lead sponsor
Oblato, Inc.
Industry
Eligibility
13 Months to 18 Years
U.S. locations
9
States / cities
Little Rock, Arkansas • Miami, Florida • Orlando, Florida + 6 more
Conditions
Dementia, Alzheimer Disease, Relationship, Marital, Caregiver Stress Syndrome
Interventions
READyR II: A, READyR II: B
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Parkinson Disease
Interventions
CBT group
Behavioral
Lead sponsor
New York Institute of Technology
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Old Westbury, New York
Conditions
Hydrocephalus
Interventions
Rhaeos Shunt Monitoring System
Device
Lead sponsor
Rhaeos, Inc.
Industry
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Peoria, Illinois
Conditions
Alzheimers Disease
Interventions
Trontinemab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Sun City, Arizona • Irvine, California + 31 more
Conditions
Hyperlipidemia
Interventions
Algorithm- and multi-professional team-supported lipid management, Guideline-directed lipid management by usual care provider
Other
Lead sponsor
Colorado Prevention Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Brain and Central Nervous System Tumors
Interventions
concurrent RAD001 10 mg/day, concurrent temozolomide, Radiation therapy, concurrent RAD001 2.5 mg/day, concurrent RAD001 5 mg/day, post-radiation RAD001 10 mg/day, post-radiation temozolomide
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
34
States / cities
Newark, Delaware • Gainesville, Florida • Jacksonville, Florida + 28 more
Conditions
Central Nervous System Metastases, Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma With Predominant Intraductal Component, Invasive Lobular Breast Carcinoma, Invasive Lobular Breast Carcinoma With Predominant in Situ Component, Liver Metastases, Lobular Breast Carcinoma in Situ, Lung Metastases, Male Breast Cancer, Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate, Mucinous Ductal Breast Carcinoma, Papillary Ductal Breast Carcinoma, Recurrent Breast Cancer, Stage IV Breast Cancer, Tubular Ductal Breast Carcinoma, Tumors Metastatic to Brain
Interventions
hyperfractionated radiation therapy, laboratory biomarker analysis, stereotactic radiosurgery
Radiation · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
1
States / cities
North Chicago, Illinois
Conditions
Huntington's Disease
Interventions
sodium phenylbutyrate
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • Iowa City, Iowa + 5 more
Conditions
Pyruvate Dehydrogenase Complex Deficiency
Interventions
Dichloroacetate (DCA), Placebo, Genotype
Drug · Other · Genetic
Lead sponsor
Saol Therapeutics Inc
Industry
Eligibility
6 Months to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
10
States / cities
Orange, California • Stanford, California • Washington D.C., District of Columbia + 7 more
Conditions
Parkinson's Disease
Interventions
Tigan®, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
27
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 24 more